Lomitapide
- Generic Name
- Lomitapide
- Brand Names
- Juxtapid, Lojuxta
- Drug Type
- Small Molecule
- Chemical Formula
- C39H37F6N3O2
- CAS Number
- 182431-12-5
- Unique Ingredient Identifier
- 82KUB0583F
- Background
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
- Indication
用于纯合子家族性高胆固醇血症以及高胆固醇血症。
- Associated Conditions
- Homozygous Familial Hypercholesterolaemia (HoFH)
- Associated Therapies
- -
Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01760187
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, Croydon, Surrey, United Kingdom
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01556906
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00943306
- Locations
- 🇨🇦
Robarts Research Institute, London, Ontario, Canada
🇨🇦Lipid Clinic and University of Montreal Community Genomic Medicine Center, Chicoutimi, Quebec, Canada
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath